Top Page
HUTCHMED (China)
(LSE:0013)
HUTCHMED (China) (0013) vs. iShares MSCI Hong Kong ETF (EWH)
HUTCHMED (China) Business Overview & Revenue Model
HUTCHMED (China) Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 610.81M | 630.20M | 838.00M | 426.41M | 356.13M | 227.98M | Gross Profit |
| 97.18M | 281.32M | 453.55M | 115.31M | 97.89M | 39.46M | EBIT |
| -120.80M | -40.61M | 18.38M | -409.77M | -336.46M | -188.95M | EBITDA |
| -110.15M | 14.11M | 67.27M | -401.11M | -329.27M | -182.89M | Net Income Common Stockholders |
| -41.97M | 37.73M | 100.78M | -410.14M | -227.66M | -194.56M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 803.51M | 836.11M | 886.34M | 631.00M | 1.01B | 435.18M | Total Assets |
| 1.26B | 1.27B | 1.28B | 1.03B | 1.37B | 724.12M | Total Debt |
| 88.59M | 89.82M | 86.13M | 23.30M | 34.07M | 35.71M | Net Debt |
| -115.36M | -64.14M | -197.46M | -289.98M | -343.48M | -199.92M | Total Liabilities |
| 508.85M | 502.34M | 536.39M | 392.57M | 333.15M | 205.17M | Stockholders Equity |
| 740.08M | 759.93M | 730.54M | 610.37M | 986.89M | 484.12M |
| Cash Flow | Free Cash Flow | ||||
| -65.34M | -17.44M | 186.65M | -305.26M | -220.98M | -81.65M | Operating Cash Flow |
| -46.98M | 497.00K | 219.26M | -268.60M | -204.22M | -62.07M | Investing Cash Flow |
| 19.39M | -96.06M | -291.14M | 296.59M | -306.32M | -125.44M | Financing Cash Flow |
| 10.27M | -30.67M | 48.66M | -82.76M | 650.03M | 296.43M |
HUTCHMED (China) Technical Analysis
HUTCHMED (China) Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | HK$20.61B | 70.01 | 5.02% | ― | -25.07% | -64.03% | |
53 Neutral | $5.22B | 3.33 | -44.36% | 7.55% | 16.78% | -0.12% | |
| $3.71B | 9.10 | 19.62% | 4.91% | ― | ― | ||
| $3.60B | 10.08 | 10.17% | 0.48% | ― | ― | ||
| €3.56B | 8.03 | 3.16% | ― | ― | |||
79 Outperform | HK$29.96B | 11.97 | 15.61% | 3.08% | 10.59% | 31.83% | |
66 Neutral | HK$12.32B | 23.57 | 5.88% | ― | -42.02% | -76.29% |
HUTCHMED (China) Corporate Events
HUTCHMED (China) Limited has released the terms of reference for its Audit Committee, which is responsible for overseeing the company’s accounting and financial reporting processes and the audit of its financial statements. The committee is composed of independent non-executive directors, with at least one member designated as an ‘audit committee financial expert’ as per U.S. regulations, ensuring compliance with both U.S. and Hong Kong financial governance standards.
The most recent analyst rating on (HK:0013) stock is a Buy with a HK$35.61 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
HUTCHMED (China) Limited has outlined the terms of reference for its Nomination Committee, which is responsible for overseeing the appointment of board members. The committee will consist of a majority of independent non-executive directors and will meet at least once a year to ensure effective governance and diversity in leadership. This move is likely to enhance the company’s corporate governance structure and ensure a balanced representation on the board, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (HK:0013) stock is a Buy with a HK$35.61 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
HUTCHMED and Innovent Biologics have announced the acceptance of their New Drug Application in China for a combination therapy of fruquintinib and sintilimab aimed at treating advanced renal cell carcinoma. This development marks a significant advancement in addressing the unmet medical needs for patients who have failed prior treatments, potentially strengthening HUTCHMED’s position in the oncology market and providing a new treatment option for stakeholders.
The most recent analyst rating on (HK:0013) stock is a Buy with a HK$35.61 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
HUTCHMED (China) Limited announced significant findings from the SACHI Phase III study, which were presented at the 2025 ASCO Annual Meeting. The study demonstrated that the combination of savolitinib and osimertinib offers a significant progression-free survival benefit over chemotherapy for patients with EGFR mutation-positive non-small cell lung cancer with MET amplification. The combination therapy showed a favorable safety profile and has led to the acceptance of a New Drug Application by the China National Medical Products Administration, potentially impacting the treatment landscape for this patient population.
The most recent analyst rating on (HK:0013) stock is a Buy with a HK$35.61 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
HUTCHMED (China) Limited announced the presentation of new clinical data at the 2025 ASCO Annual Meeting, highlighting promising results from several studies involving their compounds savolitinib, ranosidenib, fruquintinib, and surufatinib. Key findings include the successful interim analysis of the SACHI Phase III study for savolitinib in combination with osimertinib, indicating improved progression-free survival in NSCLC patients, and the promising CNS activity observed in the SAVANNAH Phase II study. Additionally, the Phase I study of ranosidenib showed durable responses in solid tumor patients with IDH mutations, and the FRUSICA-1 study demonstrated meaningful efficacy of fruquintinib plus sintilimab in advanced endometrial cancer. These results underscore HUTCHMED’s potential impact on cancer treatment, reinforcing its position in the oncology market and offering significant implications for stakeholders.
The most recent analyst rating on (HK:0013) stock is a Buy with a HK$35.61 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
HUTCHMED announced that it will present new and updated data from several studies at the AACR Annual Meeting 2025, highlighting the progress of its compounds, including savolitinib, fruquintinib, and surufatinib. These presentations underscore HUTCHMED’s ongoing efforts to advance cancer treatment options and strengthen its position in the oncology field, potentially impacting its market presence and offering new hope for patients with various types of cancer.
HUTCHMED has completed patient enrollment for a Phase II registration study of savolitinib in gastric cancer patients with MET amplification in China. The study aims to evaluate the efficacy, safety, and tolerability of savolitinib, with interim results showing promising response rates. The drug has received Breakthrough Therapy Designation from China’s National Medical Products Administration, and if successful, HUTCHMED plans to seek marketing authorization in China by late 2025. This development could enhance HUTCHMED’s position in the oncology market, potentially offering a new treatment option for patients with MET-driven gastric cancer, which currently has a poor prognosis.